# The Economics of Addiction: Why Drugs Cost Less and Kill More
The "war on drugs" rested on a simple economic theory. Make narcotics expensive enough, the logic went, and fewer people would use them. Decades of enforcement later, the opposite occurred. Street drugs cost substantially less today than they did in the 1980s and 1990s, even accounting for inflation. Meanwhile, overdose deaths have climbed to record levels, with fentanyl and other synthetic opioids driving a public health crisis that shows no signs of slowing.
Data from research organizations tracking drug prices over time reveals the stark reality. A dose of heroin that cost significantly more thirty years ago now sells for a fraction of that price. Cocaine prices have similarly collapsed. This market shift reflects several forces working simultaneously. Illicit drug production has industrialized. Trafficking networks have consolidated. Synthetic drugs like fentanyl require smaller quantities to achieve effects, reducing production and distribution costs. The result flows directly into consumers' hands as cheaper product.
The economic failure of the drug war extends beyond price alone. Higher potency has accompanied lower cost. When dealers began cutting heroin with fentanyl, a substance fifty to a hundred times stronger than morphine, they dramatically increased the lethality of street supplies. Users accustomed to heroin's effects often cannot gauge fentanyl's strength. A dose that produces the desired high becomes lethal in moments.
Public health experts attribute this transformation to prohibition itself. When demand persists despite legal penalties, prohibition creates incentives for suppliers to maximize profit per unit sold. Stronger drugs require smaller doses, smaller quantities to distribute, and lower transportation costs. Fentanyl fits this market dynamic perfectly. A kilogram of fentanyl can produce the same effect as a ton of heroin. Smuggling becomes easier. Price points drop further. The cycle reinforces itself.
The National Institute on Drug Abuse and other research organizations have extensively documented these patterns. They show that availability rather than price determines use rates for people struggling with addiction. Cheaper drugs simply mean more deaths among those already addicted, plus expanded access for new users, particularly in communities already devastated by opioid dependence.
Some jurisdictions have begun pivoting away from supply-side enforcement toward treatment and harm reduction. Supervised consumption sites, medication-assisted therapy, and naloxone distribution programs address the reality that addiction stems from complex biology and circumstance, not moral failure or insufficient deterrence. These approaches aim to keep people alive while treating the underlying condition.
The war on drugs left a specific legacy in American neighborhoods. It incarcerated millions without substantially reducing drug use or availability. Instead, it created the conditions for today's synthetic opioid epidemic. Black and Hispanic communities experienced disproportionate enforcement. Poor neighborhoods saw both criminalization and abandonment of treatment resources. Now those same communities face fentanyl's lethal consequences.
Reversing this trajectory requires acknowledging that pricing mechanisms cannot solve addiction. Supply reduction without treatment capacity simply kills more people. The evidence from other countries employing decriminalization and treatment-first policies suggests an alternative path exists, though implementing it requires abandoning decades of failed strategy and the political will to fund genuine public health responses.